Improving the symptoms that matter to patients
Immune thrombocytopenia (ITP) patients treated with REVOLADE were able to achieve significant improvements in fatigue at Week 26, with an almost three-fold increase compared with those receiving placebo [difference 3.1 (4.2 vs. 1.1 respectively), p=0.007, n=135]1*
In the EXTEND study,† at least half (50%–64%) of REVOLADE patients were able to achieve clinically meaningful improvements in health-related quality of life (HRQoL)2
REVOLADE patients have also been shown to achieve positive mean changes in all HRQoL measures during treatment, with significant improvements seen in:2
- Physical health
- Motivation and energy
- Fatigue severity
- Concerns regarding bleeding and bruising
Adjusted mean change in HRQoL score over time compared with baseline (positive change indicates improvement)2
Choose REVOLADE with confidence for a TRUSTED treatment without compromising quality of life
FACT-Th6, Functional Assessment of Cancer Therapy – Thrombocytopenia 6 Item Version; FACIT-fatigue, Functional Assessment of Chronic Illness Therapy - fatigue scale; HRQoL, health-related quality of life; ITP, immune thrombocytopenia; MEI-SF, Motivation and Energy Inventory-Short Form; SF-36v2 MCS, 36-Item Short Form Survey version 2 Mental Component Score; SF-36v2 PCS, 36-Item Short Form Survey version 2 Mental Component Score.
*The phase III, double-blind, placebo-controlled RAISE study evaluated the response of ITP patients (defined as >6 months duration with baseline platelet counts <30,000/μL) to REVOLADE over 6 months of treatment.1
†The phase III, open-label EXTEND study evaluated long-term safety and efficacy of REVOLADE in adults with ITP (defined as >6 months duration with baseline platelet counts <30,000/μL) who have completed a previous REVOLADE study. The study reviewed more than 8 years of continuous treatment; 302 patient were enrolled and 135 (45%) completed the study, 60% were treated for at least 2 years and 35% at least 3 years.2
References:
- Cheng G, et al. Lancet. 2011;377:393–402.
- Khelif A, et al. Am J Hematol. 2019;94:200–208.
